All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Australian biopharma Immutep Ltd. saw its stock price jump 165% Dec. 10, as the company reported that adding its eftilagimod alpha (IMP-321, “efti”) to paclitaxel resulted in what the company called a “promising and improving” trend toward increased overall survival in women with metastatic hormone receptor-driven breast cancer.
Australian biopharma Immutep Ltd. saw its stock price jump 165% Dec. 10, as the company reported that adding its eftilagimod alpha (IMP-321, “efti”) to paclitaxel resulted in what the company called a “promising and improving” trend toward increased overall survival in women with metastatic hormone receptor-driven breast cancer.
New and updated preclinical and clinical data presented by biopharma firms at the San Antonio Breast Cancer Symposium, Dec. 8-11, including: Amunix, Astrazeneca, Athenex, Beyondspring, Bold, Briacell, Daiichi Sankyo, Eli Lilly, Evelo, Greenwich, Immutep, Infinity, Medsir, Novartis, Oncolytics, Pharmabcine.
